Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Gustavo A Heresi, MD, MS
Study ID
NCT06992440
Phase
PHASE2
Status
Enrolling By Invitation

Conditions

  • Pulmonary Arterial Hypertension

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.

Key Dates

Start date
Jun 26, 2025
Status verified
Sep 2025
Primary completion
Jul 31, 2030
Completion
Sep 30, 2030

Study Design

Enrollment
78 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Empagliflozin
    Participants receive Empagliflozin 10 mg orally once daily for 24 weeks. Empagliflozin is over-encapsulated to match placebo.
  • Placebo Comparator: Placebo
    Participants receive placebo tablet over-encapsulated to match Empagliflozin orally once daily for 24 weeks.

Primary Outcome Measure

Change in RV ejection fraction measured by CMR [ Time Frame: 24 weeks ]

Locations (3)

FacilityCityStateZIPSite coordinators
The Johns Hopkins HospitalBaltimoreMaryland21287-
Cleveland ClinicClevelandOhio44195-
Vanderbilt University Medical CenterNashvilleTennessee37232-

Find similar trials in Baltimore, MD

By research site
The Johns Hopkins Hospital· Baltimore, MDCleveland Clinic· Cleveland, OHVanderbilt University Medical Center· Nashville, TN

Related Studies